# EDGAR Filing Document

**Accession Number:** 0001617306
**File Stem:** 0001104659-25-073781
**Filing Date:** 2025-8
**Character Count:** 11641
**Document Hash:** b5d8df116320362608b09b8b88a6059d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-073781.hdr.sgml**: 20250804

**ACCESSION NUMBER**: 0001104659-25-073781

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250731

**FILED AS OF DATE**: 20250804

**DATE AS OF CHANGE**: 20250804

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Yoskowitz Marc J
- **CENTRAL INDEX KEY:** 0001617306

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35803
- **FILM NUMBER:** 251182441

**MAIL ADDRESS:**
- **STREET 1:** C/O HOSPIRA, INC.
- **STREET 2:** 275 NORTH FIELD DRIVE
- **CITY:** LAKE FOREST
- **STATE:** IL
- **ZIP:** 60045
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mallinckrodt plc
- **CENTRAL INDEX KEY:** 0001567892
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981088325
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1226

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** COLLEGE BUSINESS & TECHNOLOGY PARK
- **STREET 2:** CRUISERATH, BLANCHARDSTOWN
- **CITY:** DUBLIN 15
- **PROVINCE COUNTRY:** L2
- **ZIP:** D15
- **BUSINESS PHONE:** 353 1 6960000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** COLLEGE BUSINESS & TECHNOLOGY PARK
- **STREET 2:** CRUISERATH, BLANCHARDSTOWN
- **CITY:** DUBLIN 15
- **PROVINCE COUNTRY:** L2
- **ZIP:** D15

## Ex-24

**Exhibit 24**

**POWER OF ATTORNEY**

The undersigned hereby makes, constitutes and appoints each of Mark A. Tyndall, Olga Khvatskaya, Stacie Phillips, Christopher Puccio and Irina Abbas, or any of them acting singly, and with full power of substitution and re-substitution, the undersigned's true and lawful attorney-in-fact (each of such persons and their substitutes being referred to herein as the "Attorney-in-Fact"), with full power to act for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to:

&nbsp;&nbsp;&nbsp;&nbsp;1. Take such actions as may be necessary or appropriate to enable the undersigned to submit and file forms,
schedules and other documents with the U.S. Securities and Exchange Commission ("SEC") utilizing the SEC's Electronic
Data Gathering and Retrieval ("EDGAR") system, which actions may include (a) enrolling the undersigned in EDGAR Next and (b)
preparing, executing and submitting to the SEC a Form ID, amendments thereto, and such other documents and information as may be necessary
or appropriate to obtain codes and passwords enabling the undersigned to make filings and submissions utilizing the EDGAR system;

&nbsp;&nbsp;&nbsp;&nbsp;2. Prepare and execute and submit (or cause to be submitted by a person appointed under <u>Section 3</u> below, as applicable) to the SEC, Mallinckrodt plc (the "Company"), and/or any national securities exchange on which the Company's
securities are listed any and all reports forms, schedules and other documents (including any amendments thereto) the undersigned is required
to file with the SEC, or which the Attorney-in-Fact considers it advisable to file with the SEC, under Section 16 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), or any rule or regulation thereunder, or under Rule 144 ("Rule 144")
under the Securities Act of 1933, as amended, with respect to any security of the Company, including Forms 3, 4 and 5 and Forms 144;

&nbsp;&nbsp;&nbsp;&nbsp;3. Act as an account administrator for the undersigned's EDGAR account, including to: (i) appoint,
remove and replace account administrators, account users, technical administrators and delegated entities; (ii) maintain the security
of the undersigned's EDGAR account, including modification of access codes; (iii) maintain, modify and certify the accuracy of information
on the undersigned's EDGAR account dashboard; (iv) act as the EDGAR point of contact with respect to the undersigned's EDGAR
account; and (v) any other actions contemplated by Rule 10 of Regulation S-T with respect to account administrators;

&nbsp;&nbsp;&nbsp;&nbsp;4. Cause the Company to accept a delegation of authority from any of the undersigned's EDGAR account
administrators and, pursuant to that delegation, authorize the Company's EDGAR account administrators to appoint, remove or replace
users for the undersigned's EDGAR account; and

&nbsp;&nbsp;&nbsp;&nbsp;5. Obtain, as the undersigned's representative and on the undersigned's behalf, information regarding
transactions in the Company's equity securities from any third party, including the Company and any brokers, dealers, employee benefit
plan administrators and trustees and the undersigned hereby authorizes any such third party to release any such information to the Attorney-in-Fact.

The undersigned acknowledges that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) This Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act in his or her discretion
on information provided to such Attorney-in-Fact without independent verification of such information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any documents prepared or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this
Power of Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his or her discretion, deems necessary
or desirable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Neither the Company nor the Attorney-in-Fact assumes any liability for the undersigned's responsibility
to comply with the requirements of Section 16 of the Exchange Act or Rule 144, any liability of the undersigned for any failure to comply
with such requirements, or any liability of the undersigned for disgorgement of profits under Section 16(b) of the Exchange Act; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's
obligations under Section 16 of the Exchange Act, including, without limitation, the reporting requirements under Section 16 of the Exchange
Act.

The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary or advisable to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by authority of this Power of Attorney.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 4 or 5 or Forms 144 with respect to the undersigned's holdings of and transactions in securities of the Company, (b) revocation by the undersigned in a signed writing filed with the SEC or delivered to the Attorneys-in-Fact or the Company, or (c) as to any Attorney-in-Fact individually, until such Attorney-in-Fact is (x) no longer employed by the Company or (y) no longer representing the Company with respect to matters related to this Power of Attorney. This Power of Attorney revokes all previous powers of attorney with respect to the subject matter of this Power of Attorney.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of July 11, 2025.

---

| |
|:---|
| /s/ Marc Yoskowitz |
| Name: Marc Yoskowitz |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Yoskowitz Marc J<br><sub>(Last) (First) (Middle)</sub><br>675 MCDONNELL BLVD.<br><sub>(Street)</sub><br>HAZELWOOD, MO 63042<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Mallinckrodt plc [ NONE ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-07-31 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 787<sup>(1)(2)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. At the Merger Effective Time (as defined in the Transaction Agreement), each share of Endo common stock held by the reporting person immediately prior to the Merger Effective Time automatically converted into the right to receive approximately $1.31 in cash and 0.2575 ordinary shares of the Issuer without interest and subject to applicable withholding. The securities reported herein were acquired by the reporting person prior to the reporting person becoming a director of the Issuer.

(2) The reporting person became a director of the Issuer immediately following the effective time of the Business Combination.

**Remarks:**
Exhibit 24 - Power of Attorney. This Form 3 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.

**Signature:** /s/ Mark Tyndall, Attorney-in-Fact  
**Date:** 2025-08-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**